-
公开(公告)号：US12018017B2
公开(公告)日：2024-06-25
申请号：US18073728
申请日：2022-12-02
发明人： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
CPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
公开(公告)号：US20240199586A1
公开(公告)日：2024-06-20
申请号：US18430679
申请日：2024-02-02
申请人： FUJIFILM Corporation
发明人： Yoshihiro JIMBO
IPC分类号： C07D403/14 , C03C17/32 , C07D401/14 , C07D417/14
CPC分类号： C07D403/14 , C03C17/32 , C07D401/14 , C07D417/14
摘要： A compound represented by Formula (1) or a tautomer thereof; a composition; a laminate; an optical film; an image forming material; and a method for producing a compound or tautomer thereof [R1 to R4: a hydrogen atom or the like, R20: a group represented by Formula (2) or the like, A: an aromatic hydrocarbon group or the like, B: a cationic aromatic hydrocarbon group or the like, *: a bonding position, with the proviso that a compound corresponding to [a], a compound corresponding to [b], and tautomers thereof are excluded. [a] A: a group represented by Formula (P), R20: a hydrogen atom, *: a bonding position, R1 and R3 are the same, and R2 and R4 are the same. [b] A: a group represented by Formula (P), R20: a group represented by Formula (2), *: a bonding position, B: a group represented by Formula (Q), R1 and R3 are the same, and R2 and R4 are the same.].
-
公开(公告)号：US20240190860A1
公开(公告)日：2024-06-13
申请号：US18551942
申请日：2021-03-24
发明人： Gabriele AMARI , Elisabetta ARMANI , Mafalda PAGANO , Marta GIULIANI , Luca RAVEGLIA , Claudia BEATO
IPC分类号： C07D417/14 , A61K31/517 , C07D401/04 , C07D413/14
CPC分类号： C07D417/14 , A61K31/517 , C07D401/04 , C07D413/14
摘要： The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
-
公开(公告)号：US20240189322A1
公开(公告)日：2024-06-13
申请号：US18516091
申请日：2023-11-21
申请人： Genzyme Corporation
发明人： John L. KANE, JR. , Gloria MATTHEWS , Markus METZ , Michael KOTHE , Jinyu LIU , Andrew SCHOLTE
IPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/50 , C07F9/6506 , C07F9/6558 , C07F9/6561
CPC分类号： A61K31/551 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D519/00 , C07F9/5022 , C07F9/6506 , C07F9/65583 , C07F9/6561
摘要： Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
-
![2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY](/abs-image/US/2024/06/06/US20240182456A1/abs.jpg.150x150.jpg)
公开(公告)号：US20240182456A1
公开(公告)日：2024-06-06
申请号：US18554778
申请日：2022-04-11
申请人： Novartis AG
发明人： Martin ALLAN , Matthew CARSON , Thomas CAYA , Lara CZABANIUK , Ming QIAN , Daniel SMITH , Troy SMITH , Liansheng SU , Chung-Yeh WU , Lihua YANG , Chun ZHANG , Ping ZHANG , Xilin ZHOU
IPC分类号： C07D405/14 , C07D413/14 , C07D417/14
CPC分类号： C07D405/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to compounds of formula (I) as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease and neuropathy. Preferred compounds are e.g. 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole derivatives and similar compounds, such as e.g. C-1, C-2, C-3, C-4 and other compounds.
-
公开(公告)号：US20240182454A1
公开(公告)日：2024-06-06
申请号：US18278234
申请日：2022-06-28
发明人： Yandong Zhang , Xianglu Li
IPC分类号： C07D403/14 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
CPC分类号： C07D403/14 , A61K31/4184 , A61K31/422 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention relates to a polycyclic compound for inhibiting RNA helicase DHX33, and an application of the compound. In particular, the present invention relates to a compound as represented by formula I or a pharmaceutically acceptable form thereof, a pharmaceutical composition comprising the same, a preparation method therefor, and a medical use thereof for preventing and/or treating DHX33-associated diseases.
-
公开(公告)号：US11999727B2
公开(公告)日：2024-06-04
申请号：US17732846
申请日：2022-04-29
发明人： Kevin M. Cottrell , John P. Maxwell
IPC分类号： C07D417/14 , A61P35/00
CPC分类号： C07D417/14 , A61P35/00
摘要： Compounds are provided according to Formula (I):
and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.-
公开(公告)号：US11999726B2
公开(公告)日：2024-06-04
申请号：US17259993
申请日：2019-07-24
IPC分类号： C07D417/14
CPC分类号： C07D417/14
摘要： The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimers disease.
-
公开(公告)号：US20240174640A1
公开(公告)日：2024-05-30
申请号：US18383523
申请日：2023-10-25
申请人： Opna Bio SA
发明人： Songyuan Shi , John Buell , Zuojun Guo , Cuong LY , Wayne Spevak , Mark Vander Wal , Jack Walleshauser , Chao Zhang , Jiazhong Zhang
IPC分类号： C07D401/14 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/107
CPC分类号： C07D401/14 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07D491/107
摘要： Disclosed are compounds of Formula I:
or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.-
公开(公告)号：US20240174634A1
公开(公告)日：2024-05-30
申请号：US18265063
申请日：2021-12-10
发明人： Christopher Stephen KERSHAW , Mohammed ALJARAH , Dan NICULESCU-DUVAZ , Mark Philip DODSWORTH , Cinzia BORDONI , Caroline SPRINGER
IPC分类号： C07D401/12 , A61P35/00 , C07D215/227 , C07D401/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
CPC分类号： C07D401/12 , A61P35/00 , C07D215/227 , C07D401/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain aldehyde dehydrogenase inhibitor compounds (also referred to herein as “ALDHI compounds”), that, inter alia, inhibit aldehyde dehydrogenase enzyme ALDH1A3. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit ALDH1A3 enzyme; to treat disorder (e.g., diseases) that are ameliorated by the inhibition of ALDHIA3 enzyme; to treat a proliferative disorder, cancer, obesity, diabetes, a cardiovascular disorder, etc.
-
-
-
-
-
-
-
-
-
搜索结果
11064 条记录 (耗时 0.038 秒)
